blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4122483

EP4122483 - ORAL PHARMACEUTICAL COMPOSITION [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  23.12.2022
Database last updated on 17.07.2024
FormerThe international publication has been made
Status updated on  07.06.2022
Most recent event   Tooltip01.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Xizang Haisco Pharmaceutical Co., Ltd.
Xingfu Jiayuan Economic Development Zone
Jieba Town, Naidong District
Lhoka, Tibet 856099 / CN
[2024/07]
Former [2023/04]For all designated states
Sichuan Haisco Pharmaceutical Co., Ltd.
No. 136 Beverley Road
Across the Taiwan Strait
Technology Industry Development Park
Wenjiang District, Chengdu
Sichuan 611130 / CN
Inventor(s)01 / FU, Ling
No.136 Beverley Road, Across The Taiwan Strait
Technology Industry Development Park, Wenjiang
District
Chengdu, Sichuan 611130 / CN
02 / WANG, Shunhong
No.136 Beverley Road, Across The Taiwan Strait
Technology Industry Development Park, Wenjiang
District
Chengdu, Sichuan 611130 / CN
03 / REN, Dong
No.136 Beverley Road, Across The Taiwan Strait
Technology Industry Development Park, Wenjiang
District
Chengdu, Sichuan 611130 / CN
04 / LI, Xiaoping
No.136 Beverley Road, Across The Taiwan Strait
Technology Industry Development Park, Wenjiang
District
Chengdu, Sichuan 611130 / CN
05 / MO, Yi
No.136 Beverley Road, Across The Taiwan Strait
Technology Industry Development Park, Wenjiang
District
Chengdu, Sichuan 611130 / CN
 [2023/04]
Representative(s)Casalonga
Casalonga & Partners
Bayerstraße 71/73
80335 München / DE
[2023/04]
Application number, filing date21772438.417.03.2021
[2023/04]
WO2021CN81224
Priority number, dateCN20201017914918.03.2020         Original published format: CN202010179149
CN20211026840512.03.2021         Original published format: CN202110268405
[2023/04]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021185265
Date:23.09.2021
Language:ZH
[2021/38]
Type: A1 Application with search report 
No.:EP4122483
Date:25.01.2023
Language:EN
[2023/04]
Search report(s)International search report - published on:CN23.09.2021
(Supplementary) European search report - dispatched on:EP22.02.2024
ClassificationIPC:A61K9/00, A61K38/07, A61K9/20, A61K9/48, A61K47/20, A61P25/04, A61K47/18, A61K9/08, A61K31/438
[2024/13]
CPC:
A61P25/04 (EP); A61K9/4858 (EP,US); A61K31/438 (EP);
A61K38/07 (EP,US); A61K47/183 (EP); A61K47/20 (EP);
A61K9/0053 (EP); A61K9/0095 (EP); A61K9/08 (EP);
A61K9/2013 (EP,US); A61K9/2027 (US); A61K9/2054 (US);
A61K9/4866 (US) (-)
C-Set:
A61K38/07, A61K2300/00 (EP)
Former IPC [2023/04]A61K38/07, A61K9/20, A61K9/48, A61P25/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/04]
TitleGerman:ORALE PHARMAZEUTISCHE ZUSAMMENSETZUNG[2023/04]
English:ORAL PHARMACEUTICAL COMPOSITION[2023/04]
French:COMPOSITION PHARMACEUTIQUE ORALE[2023/04]
Entry into regional phase07.09.2022Translation filed 
07.09.2022National basic fee paid 
07.09.2022Search fee paid 
07.09.2022Designation fee(s) paid 
07.09.2022Examination fee paid 
Examination procedure07.09.2022Amendment by applicant (claims and/or description)
07.09.2022Examination requested  [2023/04]
Fees paidRenewal fee
28.02.2023Renewal fee patent year 03
01.03.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2009263479  (MOSCHWITZER JAN P [NL], et al) [A] 1-15 * claims 4-7 *;
 [A]CN101574343  (UNIV JILIN [CN]) [A] 1-15 * claims 1-6 *;
 [A]WO2010020978  (ORAMED PHARMACEUTICALS LTD [IL]) [A] 1-15 * claims 1-31 *;
 [A]WO2019015644  (SICHUAN HAISCO PHARMACEUTICAL CO LTD [CN]) [A] 1-15 * example 8; claims 6,8,9,13 *;
 [A]  - CAROLINE TWAROG ET AL, "Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10)", PHARMACEUTICS, (20190213), vol. 11, no. 2, doi:10.3390/pharmaceutics11020078, page 78, XP055634457 [A] 1-15 * sections 5-7 *

DOI:   http://dx.doi.org/10.3390/pharmaceutics11020078
 [A]  - MORTEN ASSER KARSDAL ET AL, "Lessons learned from the clinical development of oral peptides", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BLACKWELL SCIENTIFIC PUBL, GB, (20150422), vol. 79, no. 5, doi:10.1111/BCP.12557, ISSN 0306-5251, pages 720 - 732, XP071601829 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1111/bcp.12557
 [A]  - DOI NOBUYUKI ET AL, "Absorption Enhancement Effect of Acylcarnitines through Changes in Tight Junction Protein in Caco-2 Cell Monolayers", DRUG METABOLISM AND PHARMACOKINETICS, JP, (20110101), vol. 26, no. 2, doi:10.2133/dmpk.DMPK-10-RG-071, ISSN 1347-4367, pages 162 - 170, XP093129477 [A] 1-15 * summary *

DOI:   http://dx.doi.org/10.2133/dmpk.DMPK-10-RG-071
International search[Y]US2002094346  (LIN M D HENRY C [US]) [Y] 1-2, 22-26, 30-34 * abstract, claims 1, 10 *;
 [A]CN101627049  (CARA THERAPEUTICS INC) [A] 1-34* entire document *;
 [Y]CN108135962  (CYPRUMED GMBH) [Y] 1-5, 17-34 * abstract, description paragraphs 0002-0003, 0051 *;
 [Y]WO2019015644  (SICHUAN HAISCO PHARMACEUTICAL CO LTD [CN]) [Y] 1-34 * abstract, claims 6, 8-12, description page 11 compound 8, page 14 lines 5-18 *;
 [Y]WO2019042247  (JIANGSU HENGRUI MEDICINE CO [CN]) [Y] 1-5, 16-26, 30-34 * abstract, and claims 1-2 *;
 [Y]CN109862906  (ENTERA BIO LTD) [Y] 1-16, 30-34 * abstract, claims 1, 35 *
by applicantWO2019015644
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.